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Purpose: The aim of the present study was to examine the effects of the sigma-2 receptor agonist, siramesine, on
morphology, growth, cell death, lysosomal function, and effects on extra-lysosomal proteolytic systems in human lens
epithelial cells.
Methods: Human lens epithelial cells in culture were exposed to siramesine and examined for morphological changes
using Nomarski optics or calcein. Lysosomes were evaluated using acridine orange and Magic Red (RR-cresyl violet).
Nuclear morphology was studied using Hoechst 33342 and propidium iodide. Enzymatic activities in living cells or cell
lysates were studied using fluorogenic substrates.
Results: Siramesine at low concentrations increased the cytoplasmic proteolytic activity of the proteasome and the calpain
system. Effects were also observed with respect to lysosomal morphology, acidity and function. In addition, activation of
caspase-3 and the appearance of nuclei with an apoptotic morphology was found.
Conclusions: Siramesine at low concentrations affects lens epithelial cells with perturbations of the major proteolytic
systems and lysosomal morphology, resulting in caspase activation and cell death. Siramesine may be a possible substance
for the treatment or prevention of posterior capsular opacification (PCO).
The  sigma-2  receptor  has  been  found  in  rapidly
proliferating cells, including several human and rodent tumor
cell  lines  [1,2],  and  it  has  been  used  as  a  marker  for
proliferation  in  human  breast  tumors  [3].  Agonists  to  the
sigma-2 receptor have antiproliferative and cytotoxic effects
[4,5] and have been reported to give a caspase-independent
cell death in tumor cells [6-8]. Sigma-2 receptor agonists have
also been reported to affect Ca2+-release from the endoplasmic
reticulum [9] and the inward rectifying K+ channels in the
heart  [10].  The  subcellular  localization  of  the  receptor
probably  includes  lysosomes,  mitochondria,  endoplasmic
reticulum, and the plasma membrane [11]. The endogenous
ligand(s) to the receptor is not known but some data suggest
that the ligand(s) is internalized, in part, by the endocytotic
pathway [11]. It has also been suggested that the sigma-2
receptor may be a histone binding protein [5]. An intriguing
possibility is that siramesine exerts its effects by binding to
phosphatidic acid on the bilayer surface [12]. This lipid may
have a central role as a secondary messenger in many cellular
functions.
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Siramesine  (Lu28–179;  1´-(4-(1-(4-fluorphenyl)-1H-
indol-3-yl))butan-1-yl)spiro(isobenzofuran-1(3H),4´-
piperidine) is a selective sigma-2 receptor agonist [13,14]
which has been examined in detail by Jäättelä et al. [7,15].
Their results indicate a preferential effect on the lysosome
with destabilization, enzyme leakage, oxidative stress, and
accumulation  of  autophagosomes.  These  changes  were
followed by a caspase-independent apoptosis.
Whereas sigma-2 receptors appear to be proapoptotic,
there  are  also  sigma-1  receptors;  these  in  contrast  are
antiapoptotic. Sigma-1 receptor antagonists have been shown
to inhibit proliferation in colon and mammary cancer cell
lines, which has lead to the development of potentially new
anti-cancer  drugs  [16,17].  The  expression  of  sigma-1
receptors,  as  well  as  sigma-1  receptor  antagonist-induced
apoptosis, has been demonstrated in human lens epithelial
cells [18]. To our knowledge however, there has been no
investigation  of  sigma-2  receptor-related  effects  in  lens
epithelial cells.
Posterior  capsular  opacification  (PCO)  is  the  most
common complication after cataract surgery, resulting from
proliferation  of  residual  lens  epithelial  cells  in  the  lens
capsule.  We  are  interested  in  the  possibility  of  using  the
sigma-2 receptor agonist siramesine as a drug for inhibiting
growth of lens epithelial cells to prevent the development of
PCO. A significant advantage of this drug is that clinical trials
have  been  conducted  on  siramesine  for  the  treatment  of
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819anxiety and depression. The results from these trials show that
siramesine is both non-toxic and well tolerated [19].
Experiments were thus performed to study the effects of
the  sigma-2  receptor  agonist  siramesine  on  markers  for
apoptosis and proteolytic activity in cultures of human lens
epithelial cells (HLEC).
METHODS
Materials: Human lens epithelial cells were obtained from
lenses during cataract surgery at the Eye Clinic, Sahlgrenska
University  Hospital,  Mölndal,  Sweden,  after  informed
consent. The collection was approved by the Regional Ethics
Committee of Göteborg and the Declaration of Helsinki was
followed.
The cell culture medium, RPMI-1640, and its additives
fetal bovine serum (FBS), penicillin, amphotericin, as well as
Hoechst 33342, propidium iodide, acridine orange, trypsin
inhibitor, pepstatin, leupeptin, and PMSF were all acquired
from Sigma Chemical (St. Louis, MO). Magic Red (cresyl
violet) was manufactured by Immunochemistry Technologies
(Bloomington, MN). The fluorogenic substrates Ac-Asp-Glu-
Val-Asp-AMC  (DEVD),  Suc-Leu-Leu-Val-Tyr-7-amido-4-
methylcoumarin (LLVY) and Z-Phe-Arg-AMC were from
Bachem  (Bubendorf,  Switzerland)  and  the  inhibitors
lactacystin and calpeptin were from Calbiochem (San Diego,
CA) and Novobiochem (La Jolla, CA), respectively. Calcein
was from Molecular Probes (Eugene, OR) and Siramesine was
kindly provided by Christian Thomsen, H. Lundbeck A/S,
Valby, Denmark.
Human lens epithelial cell culture and treatment: The human
lens epithelium specimens, usually 5 mm in diameter, were
placed into Eppendorf tubes, which contained culture medium
(RPMI-1640) supplemented with 10% fetal calf serum, 100
U/ml  penicillin,  0.1  mg/ml  streptomycin,  and  2  mM  L-
glutamine  and  2,5  µg/ml  amphotericin,  immediately  after
surgery. The lens epithelium specimens were later transferred
from the Eppendorf tubes to 24 well culture dishes (TPP,
Trasadingen, Switzerland) in a humidified CO2 incubator at
37 °C to allow the capsule to attach to the bottom of the culture
well. After one to two weeks, human lens epithelial cells
(HLECs) on the capsules and cells that had migrated onto the
bottom of the culture well were detached by trypsinization and
seeded in cell culture flasks (75 cm2). At confluency, cells
were subcultured by 0.25% trypsin/ EDTA treatment. For
each  experiment,  human  lens  epithelial  cells  from  one
individual, passage 6–10, were grown on white 96 well plates
with transparent bottom (Costar Corp., Cambridge, MA) in
supplemented RPMI-1640 media. The plates were incubated
in  a  humidified  CO2  incubator  at  37  °C  until  desired
confluency of the cells was obtained (approximately 105 cells
per well). Siramesine was diluted in DMSO to make a 30 mM
stock solution, which was then used when diluting to reach
desired  concentrations.  All  equipment,  such  as  pipet  tips,
tubes, and plates was coated with serum-containing media
before  addition  of  siramesine  to  avoid  binding  of  the
hydrophobic  compound  to  the  plastic  surfaces.  All
experiments  were  performed  at  least  three  times.  When
repeated,  another  cell  line  with  a  similar  phenotype  and
growth pattern was chosen. Altogether 3 different cell lines
were used. All cells derived from randomly selected age-
related cataractous lenses. No information about the age of the
donor or the cataract type was obtained. Control HLECs were
exposed to solvent at relevant concentrations.
Confocal microscopy: Morphology of cells incubated with
siramesine  was  examined  using  a  confocal  microscope
equipped  with  an  Argon,  HeNe  and  diode  laser  (Eclipse
TE300; Nikon, Tokyo, Japan). HLEC were grown on cover
glass precoated with collagen. Siramesine was added 1–3 h
before  the  dyes.  Nuclear  morphology  was  viewed  using
Hoechst  33342  (final  concentration  was18.7  µM)  or
propidium iodide (final concentration was 15 µM). General
cell morphology was evaluated using Nomarski optics or by
staining with calcein (final concentration was 5 µM). Changes
in lysosomal acidity were monitored using acridine orange
(final concentration was 2 µg/ml) and lysosomal morphology
was  visualized  using  Magic  Red  (cresyl  violet),  at  a
concentration  established  by  the  manufacturer’s  protocol
(Immunochemistry Technologies, LLC, Bloomingdale, MN).
All images were observed using Nikon Plan–Apo 20x or Plan-
Apo 60x (water immersion) objectives.
Apoptosis and mitosis: To examine apoptosis and mitosis,
HLEC were grown on 24-well plastic plates and when desired
confluence (~80%) was reached the cells were incubated with
siramesine diluted in EBSS (120 mM NaCl, 5.4 mM KCl,
0.81  mM  MgSO4,  1  mM  NaH2PO4,  5,5  mM  D-Glucose,
0.2 mM CaCl2, 25 mM Hepes, 100 U/ml penicillin, 0.1 mg/
ml streptomycin, and 2 mM L-glutamine). The siramesine
solutions were added at varying time intervals. The cells were
then  stained  with  Hoechst  and  fixed  before  counting.
Examining nuclear morphology and counting the number of
apoptotic  and  mitotic  nuclei  determined  the  extent  of
apoptosis and mitosis. Apoptotic nuclei were recognized by
chromatin condensation and disintegration of the nucleus into
apoptotic  bodies.  Mitotic  nuclei,  on  the  other  hand,  were
identified by the chromosomal positional changes that take
place during mitosis. The percentage of cells in either stage
was determined in each well. At least 300 cells were evaluated
in each well and each time point was tested in triplets.
Assay of caspase activity: Caspase-3 activity was measured
on 96-well plates of cell lysates. The cells were allowed to
grow  to  complete  confluence.  Varying  concentrations  of
siramesine diluted in EBSS were added to the cells at different
time intervals during which the plate was placed in 37 °C.
After desired incubation time, the buffer was removed and the
plate was frozen at −52 °C. The plate was thawed and the cells
were lysed in 0.1% CHAPS buffer (50 mM Tris-HCl, 100 mM
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820NaCl, 5 mM EDTA, 1 mM EGTA, 3 mM NaN3, pH 7.3) with
the addition of the following inhibitors; trypsin inhibitor (final
concentration was 5 µg/ml), pepstatin (final concentration
was 0.5 µg/ml), leupeptin (final concentration was 1.25 µg/
ml) and PMSF (final concentration was 0.5 mM). The cells
were incubated with the lysate buffer and inhibitors for 30 min
at room temperature before an equivalent volume of substrate
solution was added to each well and the caspase-3 activity was
measured  continuously  during  2  h  in  a  microplate
spectrofluorometer  (SPECTRAmax  GEMINI;  Molecular
Devices, Sunnydale CA) at an excitation of 380 nm and an
emission of 460 nm. The substrate solution contained DEVD
(final concentration was 25 µM; Ac-Asp-Glu-Val-Asp-AMC)
and DTT (final concentration was 4 mM) diluted in buffer
(50 mM Tris-HCl, 100 mM NaCl, 5 mM EDTA, 1 mM EGTA,
3  mM  NaN3,  pH  7.3)  [20].  Vmax  was  calculated  from
fluorescence data using SOFTmax PRO Version 4.8 software
(Molecular Devices, Sunnyvale, CA).
Assay of proteolytic activity in living cells: Proteolytic activity
was measured in unlysed cells using the synthetic peptide
LLVY  (Suc-Leu-Leu-Val-Tyr-AMC).  A  40  mM  stock
solution  of  LLVY  was  prepared  in  100%  DMSO.  The
substrate was diluted to 200 µM in EBSS buffer and 50 µl was
added to each well to yield a final concentration of 50 µM.
Prior to the addition of the substrate solution, the cells were
incubated  with  varying  concentrations  of  siramesine.  The
plate was placed in the spectrofluorometer and the Vmax was
calculated from continuous measurement of the fluorogenic
cleavage  product  AMC.  The  proteolytic  activity  was  also
measured after addition of known inhibitors of proteases. The
cells were grown on plates as above after which siramesine
(30 µM) was added as well as 10 µM and 50 µM, respectively,
of the inhibitors lactacystin and calpeptin. Controls with 0.1%
DMSO were included on the plate. After 30 min of incubation
with inhibitors and siramesine at 37 °C the LLVY solution
was  added  and  the  fluorescence  of  the  cleavage  product,
AMC, was measured continuously in the spectrofluorometer
at an excitation of 380 nm and an emission of 460 nm during
a period of 2 h at 37 °C to determine Vmax.
Cathepsin assay: Cathepsin activity was measured both in
living cells as well as in cell lysates made from HLEC. To
determine the activity in living cells, HLEC were grown on
96-well  plates  and  when  confluent  incubated  with
concentrations between 0 µM and 30 µM of siramesine for 1
h. After the incubation, the Cathepsin B substrate, Z-Phe-Arg-
AMC was added at a final concentration of 50 µM. The plate
was  then  placed  in  the  spectrofluorometer  and  the
fluorescence of the cleavage product was measured at an
excitation of 380 nm and an emission of 460 nm continuously
for 2 h at 37 °C. Vmax was then calculated using SOFTmax®
PRO as software. The cathepsin activity of lysed cells was
measured  using  HLEC  lysates.  Lysates  were  prepared  by
trypsinating and condensing one flask of cells into 1 ml of
lysis buffer (100 mM Na-Acetate, 50 mM NaCl, 1%Triton,
1 mM EDTA, pH 5.5) and freezing (−152 °C) over night. The
assay was run on white 96-well plates where lysate was mixed
with  siramesine  diluted  in  reaction  buffer  (100  mM
NaAcetate, 50 mM NaCl, 2 mM DTT, pH 5.5) to yield final
concentrations during measurement between 0 and 30 µM.
The mixture was allowed to incubate on ice for one hour
before  substrate  (Z-Phe-Arg-AMC)  was  added  to  a  final
concentration of 50 µM. The fluorescence was measured as
described above.
Figure  1.  Apoptosis  and  mitosis  in
human  lens  epithelial  cells  (HLEC)
following  incubation  with  siramesine.
Cells were stained with Hoechst and the
nuclear morphology was examined by
confocal  microscopy.  The  diagram
shows the average percentage of cells in
three  independent  wells  displaying
apoptotic and mitotic nuclei after 1–4 h
of incubation with siramesine or solvent
(0.1% DMSO; C). A clear proapoptotic
effect  of  siramesine  was  observed
already  after  4h.  A  tendency  for  a
reduced mitotic activity was observed at
this  time.  Results  are  displayed  with
mean±SEM,  p<0.001  (***).  The
experiment  was  repeated  three  times
with similar results.
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821Statistics: ANOVA with Dunett as post-hoc was used for
experiments with multiple data and unpaired t-tests were used
for experimental results with only two comparative groups.
Means±SEM are shown where n≥3. A p-value of <0.05 was
considered significant. SPSS, version 13.0 for Mac (SPSS
Inc., Chicago, IL) was used as statistic software.
RESULTS
Siramesine induces rapid changes in cellular morphology:
Human lens epithelial cells in culture responded to siramesine
treatment with a relatively rapid (within 4 h) change of nuclear
morphology,  such  as  condensation  and  fragmentation  of
chromatin (Figure 1). No significant changes in mitotic index
were observed, although a tendency to decrease was found in
most experiments (Figure 1). Vesicular structures, usually
with a perinuclear localization, were visible approximately 20
min  to  2  h  following  administration  of  siramesine  at
concentrations from 10 to 30 µM (Figure 2A,B). Cytoplasmic
staining with calcein revealed significant siramesine-induced
changes of cellular morphology after 2 to 3 h with 5–15 µM
siramesine (Figure 3). Many cells appeared shrunken and an
increased number of nuclei stained with propidium iodide
were  observed,  demonstrating  irreversible  membrane
dysfunction and cell death.
Siramesine activates caspases: Siramesine at a concentration
of 30 µM induced a significant increase in caspase-3 activity
from 3 h up to 6 h after exposure (Figure 4). The increase in
caspase  activity  at  4  h  was  approximately  fivefold  and
corresponded  closely  to  the  observed  changes  of  nuclear
morphology. During this time the percentage of nuclei with
apoptotic morphology increased from 1.9 percent to 9 percent.
Siramesine increases cytoplasmic protease activity: In the
intact cells siramesine rapidly caused an increased activity of
important  cytoplasmic  proteases  (Figure  5).  The  substrate
used  (LLVY)  have  previously  been  shown  to  be  a  good
substrate both for calpains and the proteasome [21]. The major
part of the increased degradation of the LLVY-substrate was
probably  due  to  proteasome  activity  as  indicated  by  the
Figure  2.  Morphological  changes  of
human lens epithelial cells (HLEC) with
perinuclear  vesicular  structures  after
siramesine treatment as revealed by DIC
optics. The control cells were exposed
to solvent, 0.1% DMSO (A) or 15 µM
of siramesine for 2.5 h at 37 °C (B).
Figure 3. Decreased viability after siramesine treatment as shown by the increased nuclear propidium iodide staining. Human lens epithelial
cells (HLEC) were exposed to solvent (0.05% DMSO; A), 5 µM siramesine (B) and 15 µM siramesine (C) for 3 h and stained with propidium
iodide (red) and calcein (green).
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822marked effect of the specific proteasome inhibitor lactacystin
(Figure 6). Addition of the calpain inhibitor calpeptin also
caused a significant change in LLVY-degrading activity, but
did not lead to a complete inhibition (Figure 6).
Siramesine affects lysosomal activity: The ability of intact
lens  epithelial  cells  to  take  up  and  degrade  the  slightly
hydrophobic  cathepsin  substrate  (FR-AMC)  was  clearly
increased after siramesine treatment (Figure 7). The increased
activity, probably mostly cathepsin B activity, was significant
already after 1 h of incubation with 5 µM of siramesine.
However, lysosomal activity assayed at pH 5.5 in vitro, using
lysates of lens epithelial cells, revealed no direct effects of
siramesine on cathepsin activity at concentrations between 0
and 30 µM (Figure 8).
Siramesine  affects  lysosomal  morphology  and  acidity:
Acridine orange staining of HLEC revealed that the lysosomal
acidity was severly reduced 4 h after administration of 10 µM
siramesine.  (Figure  9A,B).  In  an  attempt  to  visualize
lysosomal cathepsin activity in cultured cells in vivo we used
a cell-permeable substrate specific for cathepsin, Magic Red
(RR-cresyl violet) that upon cleavage will form a fluorescent
product trapped in the lysosome. Our data indicated that the
fluorescent reaction product (cresyl violet) accumulated in
vesicular structures that may correspond to lysosomes (Figure
Figure 4. Caspase 3 activity in cells after
addition  of  siramesine.  Human  lens
epithelial  cells  (HLEC)  displayed  a
substantial increase in caspase 3 activity
3–4  h  after  exposure  to  30  µM
siramesine.  The  experiment  was
repeated  four  times  and  the  diagram
shows representative results where n=3.
Mean±SEM is shown. p<0.001 (***).
Figure 5. Increased proteolytic activity
in human lens epithelial cells (HLEC)
using LLVY. The assay was performed
on  intact  cells  and  a  significant
siramesine  dependant  increase  was
observed at all times examined.  The rate
of  substrate  cleavage  was  measured
after incubating the cells with 30 µM
siramesine for 1–4 h. The figure shows
the  average  of  n=3.  Mean±SEM  is
shown.  p<0.001  (***).  Three
independent  experiments  were
performed with similar results.
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82310). The cresyl violet stained material appeared to form larger
perinuclear structures after administration of siramesine as
compared to cells exposed to solvent only.
DISCUSSION
Posterior  capsular  opacification  (PCO)  is  the  result  of
proliferation  of  residual  lens  epithelial  cells  after  cataract
surgery. Epithelial cells on the anterior lens capsule proliferate
and migrate posteriorly, causing opacification and wrinkling
of the posterior lens capsule, eventually leading to impaired
vision.  Actions  to  remove  residual  lens  epithelial  cells  at
cataract surgery or to prevent growth of these cells have not
been  entirely  successful  [22],  although  design  of  the
intraocular  lens  (IOL)  prosthesis  have  proved  to  be  of
importance [23]. A substance that affects the proliferation and
death  of  lens  epithelial  cells  without  causing  other  toxic
effects in the body would be a possible candidate to treat
patients  with  PCO.  Siramesine  may  act  both  as  a
cytoprotective  agent  that  induce  the  formation  of
autophagosomes and (at a later stage) the promotion of cell
death [24]. In the lens epithelium the drug may possibly play
a  role  in  the  delicate  regulation  of  cell  proliferation,
differentiation and cell death in the anterior and equatorial
region of the lens.
Our results clearly show that human lens epithelial cells
in culture are sensitive to relatively low concentrations of
Figure  6.  Characterization  of
extralysosomal proteolytic activity. The
results  indicates  a  marked  effect  of
siramesine on both the proteasome and
calpain proteolytic systems. Reduction
of  proteolytic  activity  in  human  lens
epithelial cells (HLEC) incubated with
30 µM siramesine (100 percent on the y-
axis) after addition of calpeptin (Cal) or
lactacystin  (Lact).  Proteolysis  was
measured  with  the  synthetic  peptide
substrate LLVY, which can be cleaved
both by the proteasome and by calpain.
Formation of the cleavage product was
measured continuously and the effects
of the proteasome inhibitor lactacystin
and the calpain-inhibitior calpeptin are
shown relative to that of the proteolytic
activity  in  cells  exposed  to  30  µM
siramesine  without  inhibitor.  The
experiment  was  repeated  three  times.
n=16. Mean±SEM is shown. p<0.001
(***).
Figure 7. Cathepsin activity in human
lens  epithelial  cells  (HLEC)  after
incubation with siramesine. The activity
of  lysosomal  cathepsins  was  clearly
sensitive to siramesine treatment. The
diagram  shows  the  dose-dependent
increase  in  proteolytic  activity  of
cathepsin after addition of siramesine 1
h  before  substrate  addition.  Vmax  is
shown with mean±SEM where n=8 and
significance levels p<0.05 (*), p<0.01
(**)  and  p<0.001  (***).  Three
independent  experiments  were
performed with similar results.
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824siramesine.  Morphological  and  proteolytical  changes
suggestive of apoptosis were seen 3 to 4 h after administration
of 30 µM siramesine. The sensitivity was comparable to that
observed in many human and rodent tumor cell lines [7]. In
contrast to previous studies [6-8], the apoptosis shown in this
study was clearly caspase-associated.
Very  early  changes  of  cellular  morphology  were
observed after siramesine exposure. These changes in the
perinuclear region may correspond to lysosomal structures
and our experiments with a cell-permeable lysosomal-specific
protease  substrate  indicated  that  the  reaction  product
accumulated in larger lysosomal structures as compared to
that of cells not treated with siramesine, which exhibited much
smaller lysosomal structures.
Changes in the activity of lysosomal enzymes indicated
increased activity already at 5 µM of siramesine. If these
results reflect a real increase in lysosomal protease activity or
an increased availability of the substrate to the cytoplasm and/
or the lysosome interior remains to be studied. Siramesine had
no effect on cathepsin activity in lysates of lens epithelial cells.
We used acridine orange to stain the acidic compartment of
the cell, roughly corresponding to the lysosomes. Our results
clearly showed that the staining decreased very early and was
heavily reduced a few hours after siramesine treatment. This
indicated that the lysosomal membrane or proton pump, at this
time,  was  compromised  and  that  the  acidic  milieu  had
disappeared.
Examination of the major cytoplasmic (extra-lysosomal)
proteolytic systems indicated that an increased proteolytic
activity  could  be  observed  already  1  h  after  siramesine
treatment.  Our  findings  thus  clearly  indicated  a  marked
sensitivity of HLEC to siramesine. Using inhibitors of these
proteolytic  systems,  we  could  demonstrate  that  a  specific
proteasome inhibitor could abolish most of the activity. A
significant  effect  was  also  observed  when  inhibiting  the
calpain system. The cytotoxic effects induced by siramisine
in HLEC may thus be initiated by perturbations of the major
proteolytic systems, the proteasome-ubiquitin system and the
Figure  8.  No  effect  of  siramesine  on
cathepsin activity in cell lysates from
human lens epithelial cells (HLEC). The
enzymatic  activity  measured  in  cell
lysates  with  final  concentrations  of
siramesine between 0 and 30 µM at a pH
of  5.5.  Leupeptin  (50  µM),  a  known
Cathepsin  B  inhibitor,  was  used  as  a
negative  control  and  displayed  a
significant drop in activity. The diagram
shows  Vmax  at  each  concentration  of
siramesine where n=3. Mean±SEM is
shown. p<0.001 (***). The experiment
was repeated twice with similar results.
Figure  9.  Lysosomal  acidity  is
decreased after siramesine treatment. As
shown by the marked decrease of red
staining indicating the alkalinization of
the  lysosomal  pH.  The  sample  was
excited with the UV–laser. Human lens
epithelial  cells  (HLEC)  were  stained
with acridine orange (red) and Hoechst
(blue)  after  incubation  with  10  µM
siramesine (B) and solvent, 1% DMSO
(A). One of two experiments is shown.
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825calpain family. The mechanism behind the high sensitivity to
siramesine in lens epithelial and tumor cells, as opposed to
other cell types, is not known. We have not observed any
differences in siramesine sensitivity between confluent and
rapidly proliferating lens epithelial cells (data not shown). It
has earlier been suggested that tumor cells have more of the
sigma-2 receptor than normal cells but others have speculated
upon  differences  in  the  signal  transduction  process  [1,7].
Another possibility could be a variation in the expression of
phosphatidic acid at the cell surface between different cell
types.
Posterior  capsular  opacification  (PCO)  is  the  most
frequent  complication  to  cataract  surgery,  with  reported
incidence numbers of 20%–40% [22]. Even though PCO can
be  treated  successfully  by  posterior  capsulotomy  using
Nd:YAG  laser,  this  treatment  has  potential  risks  such  as
development of macular edema and retinal detachment [25,
26]. An agent that can reduce the growth of residual lens
epithelial cells without exerting toxic effects on other cell
types or on neighboring tissues, is an attractive idea. However
it still remains to be elucidated if siramesine, in an intact
organism, is selective to lens epithelial cells as compared to
retinal cells. Animal studies are required to resolve this issue.
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